文献速递乳腺乳腺X线

影像生物标志物是识别起源于主要乳管的高致死性乳腺癌的关键

Imaging biomarkers are key to recognizing fatal breast cancers arising in the major ducts.
PubMed 文献 · Eur J Radiol · 2025-11-26

本研究基于本单位2008年1月至2022年6月诊断的3587例乳腺癌,采用影像生物标志物(钼靶肿瘤特征)前瞻性分类肿瘤起源部位,并与大切片组织病理学和长期结局关联。起源于主要乳管的570例乳腺导管腺癌中,产坏死亚型较产液体亚型的乳腺癌特异性死亡风险升高4.33倍(95%CI 1.73-10.84),非钙化结构扭曲亚型风险为非显著的2.51倍(95%CI 0.87-7.23),51/67例(76%)乳腺癌死亡发生于钼靶上呈碎片状铸型钙化的317例女性。

要点

  • 钼靶上碎片状铸型钙化提示高致死性乳腺导管腺癌,51/67例(76%)乳腺癌死亡见于该征象的317例女性。
  • 产坏死影像亚型较产液体亚型的乳腺癌特异性死亡风险升高4.33倍(95%CI 1.73-10.84)。
  • 非钙化结构扭曲亚型较产液体亚型的死亡风险为非显著的2.51倍(95%CI 0.87-7.23)。

核心结论

  • 识别乳腺导管腺癌亚组的影像生物标志物是控制这些恶性肿瘤的必要第一步,因为这些标志物指示肿瘤起源部位并具有预后价值;作者认为在医学界认识到新导管生成是侵袭性而非原位过程之前,难以显著降低其高致死率。

研究设计与样本

  • 前瞻性分类研究,本单位2008年1月至2022年6月诊断、随访至2023年的全部组织学证实的女性乳腺癌3587例,按钼靶肿瘤特征影像生物标志物分类肿瘤起源部位,并与大切片组织病理学和长期患者结局关联;起源于主要乳管的乳腺导管腺癌570例连续病例进一步按影像生物标志物分亚组。

关键影像表现/征象

  • 钼靶上碎片状铸型钙化见于317例女性,其中51/67例(76%)乳腺癌死亡发生于此。
  • 部分致死性病例的腋窝淋巴结活检和远处转移灶显示与新导管高度相似的结构。
  • 乳腺导管腺癌各亚组的管样结构为新导管生成过程产生的新形成的侵袭性新导管,并非预先存在的导管,可转移至淋巴结和远处器官。

诊断标准与关键数值

  • 产坏死乳腺导管腺癌亚型较产液体亚型的乳腺癌特异性死亡风险升高4.33倍(95%CI 1.73-10.84)。
  • 非钙化结构扭曲乳腺导管腺癌亚型较产液体亚型的乳腺癌特异性死亡风险为非显著的2.51倍(95%CI 0.87-7.23)。

临床应用与阅片要点

  • 作者认为,感知和识别乳腺导管腺癌各亚组的影像生物标志物是控制这些恶性肿瘤的必要第一步。
  • 作者认为,这些广泛、弥漫侵袭性恶性肿瘤的可靠影像-病理对照需要采用大切片组织病理学技术。
  • 作者认为,这些观察挑战了对这些乳腺导管腺癌病例使用「导管原位癌(DCIS)」这一术语。

局限性

  • 原文结论指出,在医学界认识到新导管生成是侵袭性而非原位致癌过程之前,不太可能显著降低其高致死率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The significant decrease in breast cancer deaths achieved by organized mammography screening programs and treatment of breast cancer at an early phase is a remarkable achievement in clinical cancer research. A remaining challenge is to recognize the breast cancers we are still failing to manage effectively, even when women attend screening regularly and receive modern therapeutic regimens. Many of these fatal tumours originate in the major lactiferous ducts through the carcinogenic process of neoductgenesis with the formation of invasive neoducts. The proposed name for these malignancies is ductal adenocarcinoma of the breast (DAB). Using imaging biomarkers correlated with large format histopathology, we sought to identify the DAB subgroups with the highest fatality.

METHOD: All histologically proven breast cancer cases (n = 3587) in women of all ages, diagnosed in our Institution from January 2008-June 2022 and followed up through 2023, were prospectively classified into their apparent site of tumour origin using imaging biomarkers mammographic tumour features. These have been correlated with large format histopathology and long-term, patient outcome. Breast cancers originating from the major lactiferous ducts (DAB) formed a subgroup of 570 consecutive cases, which were further subdivided according to their imaging biomarkers. The frequency of occurrence of the combined necrosis producing cases, the combined fluid producing cases and the non-calcified architectural distortion type DAB cases were compared with the death rate within each of these combined subgroups.

RESULTS: Patients with the necrosis-producing DAB subtypes had a significantly elevated, 4.33-fold risk of breast cancer-specific death (95% CI: 1.73-10.84) compared with the fluid-producing DAB subtypes. Patients with the non-calcified architectural distortion DAB subtype had a non-significant 2.51-fold higher risk (95 % CI: 0.87-7.23 compared with the fluid-producing DAB subtypes. The majority of breast cancer deaths, 51/67 (76 %), were in the 317 women having fragmented casting type calcifications on the mammogram. Biopsied axillary node and distant metastases of some fatal cases revealed structures closely resembling neoducts.

CONCLUSIONS: Perception and recognition of the imaging biomarkers of the DAB subgroups are necessary first steps in controlling these malignancies, since these biomarkers indicate the site of tumour origin and have documented prognostic value. Reliable imaging-histopathologic correlation of these extensive, diffusely invasive malignancies calls for the use of a large section histopathology technique. The duct-like structures of each DAB subgroup are newly formed invasive neoducts produced by the carcinogenic process of neoductgenesis; they are not pre-existing ducts and can metastasize to the lymph nodes and to distant organs. These observations challenge the use of the term ductal carcinoma in situ (DCIS) for these DAB cases. Until the medical community recognizes that neoductgenesis is an invasive, not an in situ carcinogenic process, we are unlikely to achieve a significant reduction in its high fatality rate.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Tabár L, Dean PB, Chen TH, et al. Imaging biomarkers are key to recognizing fatal breast cancers arising in the major ducts. Eur J Radiol. 2025. PMID: 41353971. doi:10.1016/j.ejrad.2025.112564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。